CDC Reduces Vaccination Recommendations, Sparking Debate

In a notable shift, the Centers for Disease Control and Prevention (CDC) announced on Monday that it has cut down the number of vaccines recommended for children, including the hepatitis B vaccine. This vaccine, a three-dose series given at birth, guards against a virus that severely harms the liver.

Health Secretary Robert F. Kennedy Jr. has long expressed skepticism about the newborn dose, even suggesting a link between its ingredients and autism, although without evidence. Just last month, he criticized the U.S. for having an “excessive” number of vaccines, and this reasoning contributed to eliminating the hepatitis B shot for newborns. A memo from the Department of Health and Human Services revealed that 20 other countries, apart from Denmark and Finland, still recommend this vaccine for all children at some point in their lives.

In the U.S., hepatitis B is a significant health issue. Public health experts estimate that over 1,800 individuals die from the virus each year. Dr. Samuel So, a surgeon who specializes in hepatitis B, stated, “It’s just really sad. This has damaged the CDC’s reputation.” There is a consensus among health experts that this reduction will likely lead to fewer vaccinated children.

In contrast, countries like Ghana are striving hard to obtain life-saving vaccine doses. Ghana faces a daunting challenge with nearly ten percent of its population suffering from chronic hepatitis B, resulting in about 10,000 new infections annually. In the U.S., the CDC estimates around 20,700 new infections each year.

Impact and Efforts in Ghana

The risks associated with hepatitis B—conditions like cirrhosis and liver cancer—are severe. In Ghana, deaths linked to these complications have surged, with 14,000 fatalities reported in 2022. Charles Adjei, the executive director of the Hepatitis Alliance of Ghana, noted that the costs of treatment are burdensome for families and the healthcare system, especially as patients still need to pay for their care.

The virus has been present for millennia and primarily spreads within communities, particularly through mother-to-child transmission. If infants miss the birth dose, they are at a high risk for this route of infection, with rates ranging from 10% to 90% based on the mother’s condition. Alarmingly, about 95% of infected infants will carry the virus for life, leading to stigmatization and severe health issues.

Interestingly, administering the initial vaccine dose within the first 24 hours of birth can greatly reduce transmission. This dose is not only cost-effective but also has proven to be about 75% to 95% effective in preventing transmission when followed by two additional doses later in childhood.

Despite a recommendation from the World Health Organization in 2009 for all countries to administer the hepatitis B vaccine at birth, its implementation in Ghana has faced hurdles. While the country has been actively working on a vaccination program since 2002, it has struggled to ensure that newborns receive this crucial first dose. The pentavalent vaccine, which is currently used, is delivered at about one month of age, often too late to prevent an infection.

“We don’t want to leave that gap open,” stated Dr. Yvonne Ayerki Nartey, a physician in Ghana. Although helpful, the pentavalent vaccine does not eliminate the risk of infection effectively. According to a Sierra Leone study, over half of children who were vaccinated still contracted hepatitis B.

Another option for immediate protection involves a concentrated dose of antibodies, yet this comes with a hefty price—around $50—far beyond what many families can afford, especially with average monthly earnings around $240.

Challenges and Advocacy

Ghana’s economic struggles, including rising inflation and debt, have further strained its health budget, making it tough to support a newborn vaccination program. Adjei laments, “We haven’t taken that bold step yet,” attributing much of the challenge to a lack of funding support.

Gavi, the organization that funds immunizations for lower-income nations, has supported Ghana for pentavalent vaccines but has not stepped in for the newborn hepatitis B vaccine due to co-financing policies. Thus, Ghana relies on its limited resources.

Efforts to raise awareness and pressure Gavi have included advocacy from prominent figures like Ghanaian rapper Okyeame Kwame, who has worked to promote the vaccine and support hepatitis B patients.

In 2018, Gavi decided to begin funding hepatitis B birth doses starting in 2021, but the pandemic delayed these efforts. Adjei recalls the ongoing struggles, saying, “It was silent for a while,” as public health initiatives faced setbacks.

Finally, Gavi announced support for newborn vaccines in 2024, allowing Ghana to plan for mass procurement. However, the Ghanaian government’s commitment to rolling out this plan has seen delays, raising concerns about whether it will launch as promised.

Despite the uncertainties, Adjei and others remain hopeful for the future, envisioning a time when Hepatitis B no longer poses a threat to new generations. “It’s been a long fight, but we’re optimistic,” he said. “We must keep pushing.”